BTLA KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
Images
Key facts
- Cell type
- Raji
- Species or organism
- Human
- Tissue
- Lymphatic
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
Alternative names
B and T lymphocyte associated, B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein, BTLA1, BTLA_HUMAN, CD272, CD272 antigen, FLJ16065, MGC129743
Recommended products
BTLA KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
Key facts
- Cell type
- Raji
- Species or organism
- Human
- Tissue
- Lymphatic
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Disease
- Lymphoma
- Concentration
Properties
- Gene name
- BTLA
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Suspension
- Gender
- Male
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water for bath approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 4x105 - 5x105 cells/mL(for initial passages it is recomended to culture the cells in the higher range of recomended seeding density). Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 4x105 cells/mL is recommended.
- A maximum of 3x106 viable cells/mL is obtainable.
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
Recommended control: Human wild-type Raji cell line (ab275473). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
CD272 also known as BTLA (B and T Lymphocyte Attenuator) is an immunoregulatory protein with a mass approximately 34 kDa. This target is part of the CD28 immunoglobulin superfamily and is expressed on the surfaces of various immune cells including T cells B cells and dendritic cells. BTLA/CD272 serves as a co-inhibitory molecule important in maintaining immune homeostasis. Its expression is influenced by factors present in the microenvironment of immune tissues.
- Biological function summary
BTLA functions as a negative regulator of immune responses by delivering inhibitory signals to immune cells upon binding to its ligand HVEM (Herpesvirus entry mediator). It forms a part of an immunological checkpoint complex that modulates lymphocyte activity to prevent overactivation and autoimmunity. This mechanism helps maintain a balance between immune defense and tolerance contributing to self-tolerance.
- Pathways
The BTLA/CD272 protein engages with pathways involved in immune checkpoints and T-cell receptor signaling. It interacts with proteins like HVEM and collaborates with receptors such as PD-1 and CTLA-4. These interactions play a role in the downregulation of T-cell responses which is essential in various immune processes. The signaling pathways influenced by BTLA/CD272 are integral in moderating immune responses cooperation and adaptation.
- Associated diseases and disorders
BTLA is associated with autoimmune diseases and cancer. In autoimmune disorders an altered expression or function of BTLA can lead to dysregulated immune responses causing tissue damage. In cancer the protein may contribute to immune evasion by tumors aiding tumor growth and progression. The interplay of BTLA with proteins such as PD-1 makes it a potential target for immunotherapy strategies in oncology and autoimmunity treatments.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Next Generation Sequencing - Human BTLA knockout Raji cell line (ab301904)
106 bp insertion and 197 bp deletion (allele 1), 132 bp insertion and 213 bp deletion (allele 2), and 230 bp deletion (allele 3) in exon 2, CCDS33819.1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com